Nirmatrelvir + ritonavir is under clinical development by Pfizer and currently in Phase II for Post-Acute Sequelae of COVID 2019 (PASC or Long COVID). According to GlobalData, Phase II drugs for Post-Acute Sequelae of COVID 2019 (PASC or Long COVID) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Nirmatrelvir + ritonavir LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nirmatrelvir + ritonavir overview
Nirmatrelvir and ritonavir (Paxlovid / Skyvira) are oral antiviral agents in which nirmatrelvir tablets co-packaged with ritonavir tablets. It is formulated as tablets, coated tablets, film coated tablets for oral route of administration. It is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid is indicated for the treatment of coronavirus disease (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19. Paxlovid is indicated for the treatment of coronavirus disease 2019 (COVID-19) for adults and children aged 12 years or older and weighing 40 kg or more. Paxlovid is indicated for the treatment of adults with mild to moderate novel coronavirus pneumonia (COVID-19) with high risk factors for progression to severe disease. Paxlovid is indicated for the treatment of coronavirus disease 2019 (COVID- 19) in adults 18 years of age and older, who do not require initiation of supplemental oxygen due to COVID-19 and are at increased risk of progression to hospitalisation or death.
Paxlovid is under development for the treatment of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and long covid. The drug candidate is a combination of nirmatrelvir [PF-07321332] tablets and ritonavir tablets. Low dose of ritonavir is given to boost the pharmacokinetics of the PF-07321332. It is administered through oral route and acts by targeting SARS-CoV-2 3C-like protease and HIV 1 Retropepsin.
Pfizer overview
Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies, and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.
For a complete picture of Nirmatrelvir + ritonavir’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.